Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Lexeo Therapeutics, Inc. ( (LXEO) ) is now available.
On June 26, 2025, Lexeo Therapeutics, Inc. held its virtual 2025 Annual Meeting of Stockholders online. During the meeting, stockholders elected Class II Directors to serve until 2028 and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (LXEO) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page.
Spark’s Take on LXEO Stock
According to Spark, TipRanks’ AI Analyst, LXEO is a Underperform.
Lexeo Therapeutics’ overall score is primarily hindered by its poor financial performance, characterized by no revenue and increasing losses. Technical analysis reflects a bearish trend, and valuation metrics are weak due to the company’s unprofitability. However, recent positive trial results offer a glimmer of hope for future prospects, slightly balancing the risks. The company’s reliance on external financing remains a critical risk factor.
To see Spark’s full report on LXEO stock, click here.
More about Lexeo Therapeutics, Inc.
Average Trading Volume: 924,982
Technical Sentiment Signal: Sell
Current Market Cap: $136.8M
Find detailed analytics on LXEO stock on TipRanks’ Stock Analysis page.